Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nevro stock price, quote, forecast and news

NVRO
US64157F1030
A12EPL

Price

5.18
Today +/-
-0.09
Today %
-1.91 %
P

Nevro stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nevro stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nevro stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nevro stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nevro's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nevro Stock Price History

DateNevro Price
9/6/20245.18 undefined
9/5/20245.28 undefined
9/4/20245.31 undefined
9/3/20245.55 undefined
8/30/20246.19 undefined
8/29/20246.34 undefined
8/28/20245.76 undefined
8/27/20245.82 undefined
8/26/20245.91 undefined
8/23/20245.80 undefined
8/22/20245.37 undefined
8/21/20245.46 undefined
8/20/20245.35 undefined
8/19/20245.72 undefined
8/16/20245.59 undefined
8/15/20245.79 undefined
8/14/20245.16 undefined
8/13/20245.50 undefined
8/12/20245.55 undefined
8/9/20246.01 undefined

Nevro Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nevro, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nevro from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nevro’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nevro. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nevro’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nevro’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nevro’s growth potential.

Nevro Revenue, EBIT and net profit per share

DateNevro RevenueNevro EBITNevro Net Income
2028e578.54 M undefined-24.92 M undefined-17.49 M undefined
2027e540.57 M undefined-42.81 M undefined-39.55 M undefined
2026e448.35 M undefined-60.76 M undefined-78.29 M undefined
2025e421.31 M undefined-76.48 M undefined-100.18 M undefined
2024e410.78 M undefined-92.16 M undefined-104.17 M undefined
2023425.17 M undefined-99.31 M undefined-92.21 M undefined
2022406.4 M undefined-98.8 M undefined3 M undefined
2021386.9 M undefined-90.9 M undefined-131.4 M undefined
2020362 M undefined-62.9 M undefined-83.1 M undefined
2019390.3 M undefined-96.5 M undefined-103.7 M undefined
2018387.3 M undefined-41.7 M undefined-49.2 M undefined
2017326.7 M undefined-29.6 M undefined-36.7 M undefined
2016228.5 M undefined-23 M undefined-31.8 M undefined
201569.6 M undefined-62.4 M undefined-67.4 M undefined
201432.6 M undefined-28.3 M undefined-30.8 M undefined
201323.5 M undefined-25.2 M undefined-26.2 M undefined
201218.2 M undefined-19.1 M undefined-19.1 M undefined

Nevro Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
18233269228326387390362386406425410421448540578
-27.7839.13115.63230.4342.9818.710.78-7.186.635.184.68-3.532.686.4120.547.04
55.5660.8765.6359.4267.1169.6370.5468.7268.7868.9167.9868.24-----
1014214115322727326824926627629000000
-19-25-28-62-23-29-41-96-62-90-98-99-92-76-60-42-24
-105.56-108.70-87.50-89.86-10.09-8.90-10.59-24.62-17.13-23.32-24.14-23.29-22.44-18.05-13.39-7.78-4.15
-19-26-30-67-31-36-49-103-83-1313-92-104-100-78-39-17
-36.8415.38123.33-53.7316.1336.11110.20-19.4257.83-102.29-3,166.6713.04-3.85-22.00-50.00-56.41
22.822.824.926.628.529.430.130.833.734.835.535.9800000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Nevro Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nevro is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
30.656.5176.8193.7276.4269.3264.5237.8588362374.4322.72
5.96.66.622.552.867.380.782.877.770.578.979.38
000000000000
9.610.114.962.485.298.19291.683.393.599.6118.68
2.81.52.945.96.56.69.84.25.21010.15
48.974.7201.2282.6420.3441.2443.8422753.2531.2562.9530.92
0.10.10.65.87.18.812.833.331.738.235.733.51
000000000000
000000000000
0000000000027.35
0000000000038.16
0.20.50.72.83.24.16.514.34.65.13.85.76
0.30.61.38.610.312.919.347.636.343.339.5104.79
49.275.3202.5291.2430.6454.1463.1469.6789.5574.5602.4635.71
                       
105.4153.20000000000.04
3.25.3293.9424.1470.9508.2552.6626.4880.7928.1934.1992.76
-65-91.2-122-189.4-221.2-257.8-306.1-409.8-492.8-624.2-607.2-699.41
00100-200-700-1,200-1,100-300600-400-3,100-243
000000000000
43.667.3172234.5249249.2245.4216.3388.5303.5323.8293.14
23.24.521.916.218.523.51623.13226.822.52
2.53.65.312.323.936.636.352.1464950.551.02
0.81.11.12.22.12.92.62.51.31.21.99.84
00000000168.8000
000000000000
5.37.910.936.442.25862.470.6239.282.279.283.38
0019.519.7138.1145152.4160.3141.8151.3186.9211.47
000000000000
0.20.10.10.51.21.92.822.42037.412.547.72
0.20.119.620.2139.3146.9155.2182.7161.8188.7199.4259.19
5.5830.556.6181.5204.9217.6253.3401270.9278.6342.57
49.175.3202.5291.1430.5454.1463469.6789.5574.4602.4635.71
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nevro provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nevro's financial health and stability.

Assets

Nevro's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nevro must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nevro after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nevro's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-18-26-30-67-31-36-49-103-83-1313-92
000012344467
000000000000
-51-3-42-54-16-5-21015-48-39
2451641628293111113121122
000223335655
0000001,0001,0001,0001,00001,000
-22-21-31-100-58-14-5-501-4124-58
000-5-3-4-8-3-6-12-7-8
15-19-10839-1314632-36920164-7
15-19-10744-12881435-363214711
000000000000
00190107000137-1720-146
1471321224312935224116206
14715212214511732346-169-249
-----6.00--1.00-3.00-14.00-8.00-8.00-10.00
000000000000
-561261-451814-21-985-16
-22.5-21.16-31.78-105.44-61.87-18.6-13.93-53.7-4.84-54.2217.14-67.42
000000000000

Nevro stock margins

The Nevro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nevro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nevro.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nevro's sales revenue. A higher gross margin percentage indicates that the Nevro retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nevro's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nevro's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nevro's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nevro. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nevro's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nevro Margin History

Nevro Gross marginNevro Profit marginNevro EBIT marginNevro Profit margin
2028e68.22 %-4.31 %-3.02 %
2027e68.22 %-7.92 %-7.32 %
2026e68.22 %-13.55 %-17.46 %
2025e68.22 %-18.15 %-23.78 %
2024e68.22 %-22.43 %-25.36 %
202368.22 %-23.36 %-21.69 %
202268.01 %-24.31 %0.74 %
202168.75 %-23.49 %-33.96 %
202069.03 %-17.38 %-22.96 %
201968.77 %-24.72 %-26.57 %
201870.57 %-10.77 %-12.7 %
201769.7 %-9.06 %-11.23 %
201667 %-10.07 %-13.92 %
201559.63 %-89.66 %-96.84 %
201465.34 %-86.81 %-94.48 %
201359.57 %-107.23 %-111.49 %
201258.24 %-104.95 %-104.95 %

Nevro Stock Sales Revenue, EBIT, Earnings per Share

The Nevro earnings per share therefore indicates how much revenue Nevro has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nevro earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nevro's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nevro’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nevro's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nevro Revenue, EBIT and net profit per share

DateNevro Sales per ShareNevro EBIT per shareNevro Earnings per Share
2028e15.52 undefined0 undefined-0.47 undefined
2027e14.5 undefined0 undefined-1.06 undefined
2026e12.03 undefined0 undefined-2.1 undefined
2025e11.3 undefined0 undefined-2.69 undefined
2024e11.02 undefined0 undefined-2.79 undefined
202311.82 undefined-2.76 undefined-2.56 undefined
202211.45 undefined-2.78 undefined0.08 undefined
202111.12 undefined-2.61 undefined-3.78 undefined
202010.74 undefined-1.87 undefined-2.47 undefined
201912.67 undefined-3.13 undefined-3.37 undefined
201812.87 undefined-1.39 undefined-1.63 undefined
201711.11 undefined-1.01 undefined-1.25 undefined
20168.02 undefined-0.81 undefined-1.12 undefined
20152.62 undefined-2.35 undefined-2.53 undefined
20141.31 undefined-1.14 undefined-1.24 undefined
20131.03 undefined-1.11 undefined-1.15 undefined
20120.8 undefined-0.84 undefined-0.84 undefined

Nevro business model

Nevro Corp is a global leader in innovative medical products and therapy systems. The company was founded in 2006 and is headquartered in Redwood City, California. Nevro Corp is a pioneer in the development of novel implantable medical technologies and has brought a variety of products to the market since its founding, enabling revolutionary advances in pain therapy. Nevro Corp's business model is based on the production, marketing, and sale of implantable neuromodulation devices that can reduce or even eliminate chronic pain in patients. These devices are able to send electrical signals to individual nerve fibers to target and treat pain in specific areas of the body. With this innovative technology, Nevro Corp has revolutionized the pain therapy market and filled a niche that conventional treatment methods could not address. Nevro Corp has various divisions and branches worldwide. An important area of the company is research and development, where new and innovative pain therapy technologies are constantly being developed. Another division is marketing, where the company's products are sold to medical specialists, hospitals, and clinics worldwide. In addition, Nevro Corp also offers training and education to inform medical professionals about the company and its products. The products offered by Nevro Corp include implantable neuromodulation systems such as the Senza system and the HF10 system. The Senza system is a spinal cord stimulator that is controlled via a remote and sends electrical impulses to the spinal cord to relieve pain in the arms, legs, and back. The HF10 system works with high-frequency technology and was developed to treat chronic pain in the lower back. In addition to these products, Nevro Corp has also introduced a range of accessories and enhancements to facilitate the operation and maintenance of the implantable devices. These include, for example, wireless chargers or a special remote control that allows patients to individually adjust their therapy. In summary, Nevro Corp is an innovative and successful provider of medical products and therapy systems specializing in pain therapy. With sophisticated technology, state-of-the-art research and development, and a dedicated workforce, the company has made a significant contribution to improving the quality of life for millions of patients worldwide and will continue to develop innovative and effective therapies in the future. Nevro is one of the most popular companies on Eulerpool.com.

Nevro SWOT Analysis

Strengths

Nevro Corp exhibits several strengths that contribute to its success:

  • Advanced technology: Nevro Corp utilizes state-of-the-art neurostimulation technology, giving it a competitive edge.
  • Strong intellectual property: The company holds numerous patents, safeguarding its technology and providing market exclusivity.
  • Established brand: Nevro Corp has developed a reputable brand known for its quality and innovative medical devices.
  • Effective marketing strategy: The company effectively promotes its products to healthcare professionals and potential customers.
  • Global presence: Nevro Corp has expanded its market reach and operates in multiple countries, boosting its growth potential.

Weaknesses

Despite its strengths, Nevro Corp faces certain weaknesses that could hinder its performance:

  • Relatively higher costs: The production and distribution costs of Nevro Corp's advanced devices can be higher compared to competitors.
  • Dependency on key markets: The company's success heavily relies on a few key markets, making it vulnerable to fluctuations in those regions.
  • Limited product range: Nevro Corp's product portfolio is focused on neurostimulation devices, limiting its diversification opportunities.
  • Market competition: The neurostimulation industry is highly competitive, with other established players and new entrants vying for market share.

Opportunities

Nevro Corp has several opportunities to capitalize on in the market:

  • Expanding applications: There is potential to further develop and explore new medical applications for neurostimulation technology.
  • Emerging markets: Nevro Corp can target and expand into emerging markets where there is increasing demand for advanced medical devices.
  • Innovation and R&D: Continued investment in research and development can lead to the introduction of new and improved products.
  • Partnerships and collaborations: Collaborating with healthcare institutions and professionals can enhance the adoption of Nevro Corp's technologies.

Threats

Nevro Corp faces various threats that may impact its growth and profitability:

  • Regulatory challenges: Evolving regulations and compliance requirements can pose obstacles to product development and market entry.
  • Market saturation: The neurostimulation market may become saturated, making it difficult for Nevro Corp to maintain its market share.
  • Technological advancements: Rapid technological advancements by competitors can render Nevro Corp's current offerings obsolete.
  • Economic factors: Economic downturns or financial instability can negatively influence the purchasing power and demand for medical devices.

Nevro Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nevro historical P/E ratio, EBIT, and P/S ratio.

Nevro shares outstanding

The number of shares was Nevro in 2023 — This indicates how many shares 35.981 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nevro earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nevro's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nevro’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nevro's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Nevro.

Nevro latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.7 -0.53  (24.11 %)2024 Q2
3/31/2024-1.07 -0.58  (46.01 %)2024 Q1
12/31/2023-0.5 -0.25  (49.9 %)2023 Q4
9/30/2023-0.78 -0.65  (17.09 %)2023 Q3
6/30/2023-0.7 -0.69  (2.06 %)2023 Q2
3/31/2023-1.06 -0.98  (7.81 %)2023 Q1
12/31/2022-0.5 -0.54  (-8.56 %)2022 Q4
9/30/2022-0.1 2.22  (2,337.9 %)2022 Q3
6/30/2022-0.83 -0.71  (14.8 %)2022 Q2
3/31/2022-1.12 -0.98  (12.71 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Nevro stock

Eulerpool World ESG Rating (EESG©)

45/ 100

🌱 Environment

24

👫 Social

66

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Nevro list of shareholders

%
Name
Stocks
Change
Date
8.52 % Armistice Capital LLC3,176,000-280,00012/31/2023
8.08 % ArrowMark Colorado Holdings, LLC3,011,059542,94912/31/2023
7.62 % BlackRock Institutional Trust Company, N.A.2,841,578268,12212/31/2023
5.82 % Engaged Capital, LLC2,168,16302/20/2024
5.68 % Fred Alger Management, LLC2,119,2661,065,45412/31/2023
4.76 % Braidwell LP1,776,368012/31/2023
3.23 % D. E. Shaw & Co., L.P.1,202,98469,83512/31/2023
2.77 % Two Sigma Investments, LP1,033,8512,00112/31/2023
2.75 % Rock Springs Capital Management LP1,025,000-186,60012/31/2023
2.73 % Fidelity Management & Research Company LLC1,016,3501,21812/31/2023
1
2
3
4
5
...
10

Nevro Executives and Management Board

Mr. D. Keith Grossman62
Nevro Executive Chairman of the Board (since 2019)
Compensation 17.77 M
Mr. Kashif Rashid49
Nevro Senior Vice President, General Counsel, Company Secretary
Compensation 3.24 M
Mr. Christopher Christoforou53
Nevro Senior Vice President - Technical Operations
Compensation 2.87 M
Mr. Roderick Macleod56
Nevro Chief Financial Officer, Senior Vice President
Compensation 2.74 M
Mr. Michael DeMane66
Nevro Lead Independent Director (since 2011)
Compensation 284,995
1
2
3
4

Most common questions regarding Nevro

What values and corporate philosophy does Nevro represent?

Nevro Corp represents a strong commitment to improving the lives of patients suffering from chronic pain. With a focus on innovation and advanced technology, Nevro prioritizes patient-centered solutions. The company's corporate philosophy revolves around providing effective and long-lasting relief to individuals in need. Nevro Corp aims to enhance the quality of life by offering non-opioid, evidence-based therapies that deliver superior results. By combining scientific expertise, cutting-edge research, and a patient-centric approach, Nevro Corp strives to make a meaningful impact in the field of chronic pain management.

In which countries and regions is Nevro primarily present?

Nevro Corp is primarily present in various countries and regions worldwide. The company has a global presence and operates in key markets including the United States, Europe, Australia, and Canada. With its innovative medical technology solutions, Nevro Corp aims to improve the lives of patients suffering from chronic pain across these regions.

What significant milestones has the company Nevro achieved?

Nevro Corp, a leading medical device company, has achieved several significant milestones. Firstly, the company developed the breakthrough Senza® system, a spinal cord stimulation platform that offers superior pain relief for patients suffering from chronic pain. This innovative technology has revolutionized the field of neuromodulation. Furthermore, Nevro Corp successfully obtained FDA approval for the Senza system, allowing them to market it in the United States. The company has expanded its global presence as well, receiving regulatory approvals in various countries worldwide. These achievements have solidified Nevro Corp's position as a pioneering entity in the medical device industry, dedicated to improving the lives of patients worldwide.

What is the history and background of the company Nevro?

Nevro Corp is a medical device company that specializes in developing innovative solutions for the treatment of chronic pain. Founded in 2006, Nevro has been a pioneer in the field of spinal cord stimulation. The company's flagship product, the Senza System, is designed to provide long-lasting pain relief without the side effects of traditional opioids. With a strong focus on research and development, Nevro has continued to expand its product portfolio and establish itself as a leader in the industry. Today, Nevro is trusted by healthcare professionals worldwide for its advanced therapies and commitment to improving patients' quality of life.

Who are the main competitors of Nevro in the market?

The main competitors of Nevro Corp in the market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, and Stryker Corporation.

In which industries is Nevro primarily active?

Nevro Corp is primarily active in the medical device industry.

What is the business model of Nevro?

Nevro Corp, a leading medical device company, operates on a unique business model. They specialize in developing and commercializing innovative solutions for the treatment of chronic pain. Nevro Corp's flagship product, the Senza® system, stands as a breakthrough technology in the field of spinal cord stimulation. This system offers patients suffering from chronic pain a non-opioid alternative for managing their condition. By focusing on pioneering therapies and eluding traditional opioid-based pain treatments, Nevro Corp is dedicated to enhancing the quality of life for individuals struggling with chronic pain conditions. With its innovative business approach, Nevro Corp aims to revolutionize pain management solutions in the healthcare industry.

What is the P/E ratio of Nevro 2024?

The Nevro P/E ratio is -1.79.

What is the P/S ratio of Nevro 2024?

The Nevro P/S ratio is 0.45.

What is the AlleAktien quality score of Nevro?

The AlleAktien quality score for Nevro is 6/10.

What is the revenue of Nevro 2024?

The expected Nevro revenue is 410.78 M USD.

How high is the profit of Nevro 2024?

The expected Nevro profit is -104.17 M USD.

What is the business model of Nevro

Nevro Corp is a globally operating, publicly traded company that specializes in the development and marketing of innovative medical products for the treatment of chronic pain. The company's business model is based on the use of groundbreaking technologies to alleviate pain in millions of patients worldwide. The company operates in two business segments: manufacturing and product services, as well as research and development. Product services include the marketing of both implanted and external pain relief devices, including the flagship product Senza®. These devices utilize a novel technology called HF10® to effectively combat pain. Unlike traditional devices that promise pain relief through electrical signals, HF10® uses state-of-the-art high-frequency technology to stimulate the spinal cord, resulting in deeper and more effective pain relief. In addition to the Senza® product line, Nevro also has several micro-catheter solutions in its portfolio. These catheters also use HF10® technology, but in a different way for pain treatment. The company is committed to continuously developing and bringing to market new, innovative pain relief solutions to improve the lives of patients worldwide. Nevro Corp's R&D department focuses on pain research and the development of pain relief technologies. The company collaborates with leading research institutions worldwide and invests sustainably in clinical research to improve the effectiveness of its products and obtain approvals and further market clearances in various countries. Furthermore, Nevro also offers a wide range of services to support hospitals and medical professionals in the provision of pain therapies and treatments. This includes a training program for medical personnel to ensure safe and effective use of the devices, as well as a support team available around the clock to address questions and technical issues. Nevro Corp is committed to creating a comprehensive pain relief experience for patients, healthcare professionals, and stakeholders. The company relies on a combination of innovative technologies, clinical research, and expert services to achieve this goal. In summary, Nevro Corp offers pain solutions based on its groundbreaking HF10® technology. The devices demonstrate high effectiveness in pain relief and are one of the most recommended pain therapies in modern clinics. The company continuously invests in research and development to improve its technology and introduce new products to the market. Nevro Corp supports doctors, medical personnel, and patients with a wide range of services to ensure that all parties have access to safe and effective pain treatment.

What is the Nevro dividend?

Nevro pays a dividend of 0 USD distributed over payouts per year.

How often does Nevro pay dividends?

The dividend cannot currently be calculated for Nevro or the company does not pay out a dividend.

What is the Nevro ISIN?

The ISIN of Nevro is US64157F1030.

What is the Nevro WKN?

The WKN of Nevro is A12EPL.

What is the Nevro ticker?

The ticker of Nevro is NVRO.

How much dividend does Nevro pay?

Over the past 12 months, Nevro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nevro is expected to pay a dividend of 0 USD.

What is the dividend yield of Nevro?

The current dividend yield of Nevro is .

When does Nevro pay dividends?

Nevro pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nevro?

Nevro paid dividends every year for the past 0 years.

What is the dividend of Nevro?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nevro located?

Nevro is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nevro kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nevro from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did Nevro pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of Nevro in the year 2023?

In the year 2023, Nevro distributed 0 USD as dividends.

In which currency does Nevro pay out the dividend?

The dividends of Nevro are distributed in USD.

All fundamentals about Nevro

Our stock analysis for Nevro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nevro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.